Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sézary syndrome: its enhancement by interferon-gamma (IFN-gamma) and IL-12 and fluctuations in association with disease activity.

N Seo, Y Tokura, K Matsumoto, F Furukawa, M Takigawa
Author Information
  1. N Seo: Department of Dermatology, Hamamatsu University School of Medicine, Japan.

Abstract

Sézary syndrome (SzS) is the leukaemic variant of cutaneous T cell lymphoma (CTCL), whose malignant T cells are of the Th2 type in most cases. In this study we investigated the tumouricidal activity of cytotoxic T lymphocytes (CTL) present in peripheral blood of a patient with Th2-type SzS, focusing on the effect of IL-2, IFN-gamma and IL-12 on their cytotoxic activity, and the relationship between their lytic capacity and the patient's clinical course. At four different time points during a 2-month clinical period, CD4+CD7- Sézary cells and CD8+ cells were separated from the patient's circulating cells. CD8+ cells were cultured with chemically attenuated, purified Sézary cells in the presence of IL-2 to develop specific cytotoxicity. The CD8+ cells thus cultured exhibited lytic activity against autologous Sézary cells. Concomitant addition of IFN-gamma or IL-12 exerted a synergistic cytolytic effect with IL-2 on the tumour cells. Cytotoxicity inhibition studies using MoAbs revealed that the cytotoxicity operated in MHC class I-, CD8- and alphabeta T cell receptor-dependent manners. Furthermore, eight CD8+ T cell clones generated from cultured CD8+ cells exhibited a strong cytotoxicity against Sézary cells in an MHC class I-restricted fashion. During the clinical course, the activity of generated CTL and the number of CD8+ cells were inversely correlated with disease activity as assessed by the serum level of lactate dehydrogenase. These findings suggest that CTL down-regulate the growth of malignant T cells in this long-standing disease. Since Th2 cytokines such as IL-4 down-modulate CTL activity, CTL are assumed to be usually suppressed in SzS, whose malignant T cells are of Th2 type. It is likely that the administration of IFN-gamma normalizes this Th2-skewing state, activates CTL, and thus exerts the therapeutic effectiveness in the treatment of CTCL.

References

  1. Arch Dermatol. 1993 Apr;129(4):486-9 [PMID: 8466223]
  2. J Exp Med. 1993 Apr 1;177(4):1199-204 [PMID: 8096238]
  3. Immunol Today. 1993 Jun;14(6):270-4 [PMID: 8104408]
  4. Cancer Immunol Immunother. 1994 Apr;38(4):277-80 [PMID: 8168123]
  5. Am J Clin Oncol. 1994 Jun;17(3):255-63 [PMID: 8192114]
  6. Annu Rev Immunol. 1994;12:337-65 [PMID: 8011285]
  7. J Invest Dermatol. 1994 Jul;103(1):29-33 [PMID: 8027577]
  8. Cancer Res. 1994 Aug 15;54(16):4430-5 [PMID: 7913876]
  9. J Immunol. 1995 Feb 1;154(3):1491-8 [PMID: 7822812]
  10. Science. 1995 Feb 17;267(5200):1016-8 [PMID: 7863326]
  11. Cancer Immunol Immunother. 1995 Jun;40(6):358-66 [PMID: 7627992]
  12. Nat Med. 1996 Jan;2(1):52-8 [PMID: 8564842]
  13. J Exp Med. 1996 Jan 1;183(1):7-11 [PMID: 8551246]
  14. J Am Acad Dermatol. 1996 Feb;34(2 Pt 2):368-74 [PMID: 8655729]
  15. J Invest Dermatol. 1996 Sep;107(3):392-7 [PMID: 8751976]
  16. Nature. 1996 Nov 14;384(6605):109-10 [PMID: 8906779]
  17. Eur J Immunol. 1996 Nov;26(11):2736-41 [PMID: 8921963]
  18. J Invest Dermatol. 1996 Dec;107(6):827-32 [PMID: 8941669]
  19. Blood. 1968 Jun;31(6):719-26 [PMID: 4231743]
  20. J Am Acad Dermatol. 1980 Feb;2(2):89-106 [PMID: 6988470]
  21. J Immunol. 1981 Aug;127(2):505-9 [PMID: 6166672]
  22. J Invest Dermatol. 1983 Nov;81(5):392-7 [PMID: 6226746]
  23. J Am Acad Dermatol. 1983 Dec;9(6):957-60 [PMID: 6315791]
  24. Proc Natl Acad Sci U S A. 1985 Nov;82(22):7701-5 [PMID: 3865189]
  25. Anal Biochem. 1987 Apr;162(1):156-9 [PMID: 2440339]
  26. Cell Immunol. 1988 Feb;111(2):461-72 [PMID: 2827898]
  27. J Immunol. 1988 Jun 15;140(12):4245-52 [PMID: 2967332]
  28. J Immunol. 1988 Oct 1;141(7):2349-51 [PMID: 3262658]
  29. N Engl J Med. 1988 Dec 22;319(25):1676-80 [PMID: 3264384]
  30. Annu Rev Immunol. 1989;7:145-73 [PMID: 2523712]
  31. J Immunol. 1989 May 15;142(10):3452-61 [PMID: 2654291]
  32. J Exp Med. 1989 Sep 1;170(3):827-45 [PMID: 2504877]
  33. J Exp Med. 1989 Nov 1;170(5):1751-6 [PMID: 2530302]
  34. Adv Immunol. 1989;47:187-376 [PMID: 2683611]
  35. J Am Acad Dermatol. 1990 Apr;22(4):602-7 [PMID: 1690762]
  36. Blood. 1990 Oct 1;76(7):1361-8 [PMID: 1698478]
  37. J Natl Cancer Inst. 1991 Mar 20;83(6):400-4 [PMID: 1999847]
  38. J Exp Med. 1991 Apr 1;173(4):869-79 [PMID: 1672545]
  39. Arch Dermatol. 1991 Oct;127(10):1511-6 [PMID: 1929458]
  40. Immunol Today. 1991 Dec;12(12):447-55 [PMID: 1723878]
  41. J Invest Dermatol. 1992 Jul;99(1):90-4 [PMID: 1607682]
  42. Science. 1993 Apr 23;260(5107):547-9 [PMID: 8097338]

MeSH Term

Antigens, Neoplasm
Cytokines
Cytotoxicity, Immunologic
Humans
Interferon-gamma
Interleukin-12
Lymphocyte Activation
Male
Middle Aged
Sezary Syndrome
Skin Neoplasms
Th2 Cells
Tumor Cells, Cultured

Chemicals

Antigens, Neoplasm
Cytokines
Interleukin-12
Interferon-gamma

Word Cloud

Created with Highcharts 10.0.0cellsTactivitySézaryCTLCD8+IFN-gammaSzScellmalignantTh2cytotoxicIL-2IL-12clinicalculturedcytotoxicitydiseaseCTCLwhosetypeTh2-typeeffectlyticpatient'scoursethusexhibitedMHCclassgeneratedsyndromeleukaemicvariantcutaneouslymphomacasesstudyinvestigatedtumouricidallymphocytespresentperipheralbloodpatientfocusingrelationshipcapacityfourdifferenttimepoints2-monthperiodCD4+CD7-separatedcirculatingchemicallyattenuatedpurifiedpresencedevelopspecificautologousConcomitantadditionexertedsynergisticcytolytictumourCytotoxicityinhibitionstudiesusingMoAbsrevealedoperatedI-CD8-alphabetareceptor-dependentmannersFurthermoreeightclonesstrongI-restrictedfashionnumberinverselycorrelatedassessedserumlevellactatedehydrogenasefindingssuggestdown-regulategrowthlong-standingSincecytokinesIL-4down-modulateassumedusuallysuppressedlikelyadministrationnormalizesTh2-skewingstateactivatesexertstherapeuticeffectivenesstreatmentTumour-specificlymphocytesyndrome:enhancementinterferon-gammafluctuationsassociation

Similar Articles

Cited By